# DEVELOPING DOSIMETRY OF RADIONUCLIDES GIVEN FOR THERAPY

> **NIH NIH R01** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 1990 · $221,850

## Abstract

DESCRIPTION:  (Adapted from the application) This research is to improve
quantification of radiation absorbed dose to tumors in patients following
administration of therapeutic amounts of radiopharmaceuticals using
single-photon emission computed tomography (SPECT).  The macro-dosimetric
result is to be correlated with local response to therapy and a
tracer-imaging protocol will be developed.  Non-Hodgkins' B-cell lymphoma
patients are being successfully treated by I-131 labeled monoclonal
antibodies.  A dose-monitoring protocol has improved on standard procedure
and is producing more plausible dose-response curves.  The investigators
will increase the data-processing efficiency in order to apply it to more
patients.  They will also further improve SPECT quantitative accuracy as
follows:  a) To determine when energy extrapolation of x-ray computed
tomography (CT) values for SPECT attenuation correction needs to be
replaced by radionuclide transmission scanning, they will compare the two
methods for an anthropomorphic phantom.  b) To extend accurate correction
for Compton scattering they will characterize by Monte-Carlo simulation
where the dual-energy-window method begins to fail.  They will employ
spectral fitting, using a special computer to acquire local energy spectra.
c) To obtain accurate results from CT regions of interest (ROIs)
superimposed on SPECT slices, they will develop a region-growing computer
program that accounts for poorer SPECT resolution and slight misalignments.
They will also improve accuracy of the dosimetry by investigating (1) the
intra-observer variability of the CT tumor volume, (2) the shape of the
conjugate-view time-activity curve (CV TAC), and (3) the behavior of %
uptake as administered activity is increased.  To develop dosimetric
estimation from SPECT tracer studies, they will employ constrained,
least-squares fitting of the projection data to compensate for poor
counting statistics.  Finally, to gain fuller information from human-tumor
studies in animals, a miniature, implantable beta spectrometer will be
developed, calibrated, and tested.

## Key facts

- **NIH application ID:** 3177082
- **Project number:** 2R01CA038790-06
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **SAM.gov UEI:** GNJ7BBP73WE9
- **Principal Investigator:** KENNETH F KORAL
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1990
- **Award amount:** $221,850
- **Award type:** 2
- **Project period:** 1985-09-01 → 1995-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3177082

## Citation

> US National Institutes of Health, RePORTER application 3177082, DEVELOPING DOSIMETRY OF RADIONUCLIDES GIVEN FOR THERAPY (2R01CA038790-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3177082. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*